It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Many older patients with COVID-19 likely have co-morbid osteoporosis. We investigated the clinical outcomes of COVID-19 patients with osteoporosis. This was a retrospective cohort study using national claims data from Korea encoded in the common data model. Patients aged ≥ 50 years diagnosed with COVID-19 infection between January 2020 and April 2022 were included and stratified into two groups according to a history of osteoporosis. Clinical outcomes of COVID-19 infection were analyzed using logistic regression analysis after large-scale propensity score stratification. Of the 597,011 patients with COVID-19 included in the study, 105,172 had a history of osteoporosis. In patients with a history of osteoporosis, the odds of mortality decreased (odds ratio [OR] 0.82, P < 0.002), whereas most clinical outcomes of COVID-19 did not exhibit differences compared to those without such a history. Osteoporosis patients with a history of fractures showed increased odds of pneumonia, hospitalization, major adverse cardiac events, venous thromboembolism, and mortality, compared to patients without osteoporosis (ORs 1.34–1.58, P < 0.001 to P = 0.001). Our study suggests that patients with severe osteoporosis who have experienced fractures have an elevated risk of severe complications with COVID-19, while osteoporosis patients without fractures who have sought medical attention have a lower risk of mortality.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Inha University Hospital, Inha University School of Medicine, Department of Endocrinology and Metabolism, Incheon, Republic of Korea
2 Gyeongsang National University Hospital, Department of Research Planning, Jinju, Republic of Korea (GRID:grid.411899.c) (ISNI:0000 0004 0624 2502)
3 Biomedical Research Institute, Inha University Hospital, Incheon, Republic of Korea (GRID:grid.411605.7) (ISNI:0000 0004 0648 0025)
4 Big Data Department, Health Insurance Review and Assessment Service, Wonju, Republic of Korea (GRID:grid.467842.b) (ISNI:0000 0004 0647 5429)
5 Inha University Hospital, Inha University School of Medicine, Department of Endocrinology and Metabolism, Incheon, Republic of Korea (GRID:grid.467842.b)
6 Inha University Hospital, Inha University School of Medicine, Department of Orthopedic Surgery, Incheon, Republic of Korea (GRID:grid.467842.b)




